Efficacy and safety of once-weekly semaglutide vs sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with type 2 diabetes (SUSTAIN 2)

被引：0
|
作者：
Ahren, B. [1 ]
Comas, L. Masmiquel [2 ]
Kumar, H. [3 ]
Sargin, M. [4 ]
Karsbol, J. Derving [5 ]
Jacobsen, S. Hald [5 ]
Chow, F. [6 ]
机构：
[1] Lund Univ, Lund, Sweden
[2] Hosp Quiron Palmaplanas, Palma De Mallorca, Spain
[3] Amrita Inst Med Sci & Res Ctr, Kochi, India
[4] Kartal Lufti Kirdar Training & Res Hosp, Istanbul, Turkey
[5] Novo Nordisk AS, Soborg, Denmark
[6] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
767
引用
收藏
页码：S365 / S365
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of once-weekly semaglutide vs sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with Type 2 diabetes (SUSTAIN 2)
    Ahren, B.
    Comas, L. M.
    Kumar, H.
    Sargin, M.
    Karsbol, J. D.
    Jacobsen, S. H.
    Chow, F.
    DIABETIC MEDICINE, 2017, 34 : 145 - 145
  • [2] Efficacy and Safety of Once-Weekly Semaglutide vs. Sitagliptin as Add-on to Metformin and/or Thiazolidinediones after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 2)
    Ahren, Bo
    Comas, Luis Masmiquel
    Kumar, Harish
    Sargin, Mehmet
    Karsbol, Julie Derving
    Jacobsen, Sanja Hald
    Chow, Francis
    DIABETES, 2016, 65 : A48 - A48
  • [3] Efficacy and safety of once-weekly semaglutide versus sitagliptin as add-on to metformin and/or thiazolidinediones in subjects with T2D (SUSTAIN 2)
    Chow, Francis
    Ahren, Bo
    Comas, Lluis Masmiquel
    Kumar, Harish
    Sargin, Mehmet
    Karsbol, Julie Derving
    Jacobsen, Sanja Hald
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S122 - S122
  • [4] Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3)
    Ahmann, Andrew
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders Gaarsdal
    Annett, Miriam
    Aroda, Vanita
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S51 - S51
  • [5] Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3)
    Ahmann, A.
    Capehom, M.
    Charpentier, G.
    Dotta, E.
    Henkel, E.
    Lingvay, I.
    Holst, A. Gaarsdal
    Annett, M.
    Aroda, V.
    DIABETOLOGIA, 2016, 59 : S76 - S76
  • [6] Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5)
    Rodbard, H.
    Lingvay, I.
    Reed, J.
    de la Rosa, R.
    Rose, L.
    Sugimoto, D.
    Araki, E.
    Chus, P. -L.
    Wijayasingh, N.
    Norwood, P.
    DIABETOLOGIA, 2016, 59 : S364 - S365
  • [7] Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with Type 2 diabetes (SUSTAIN 5)
    Rodbard, H.
    Lingvay, I.
    Reed, J.
    de la Rosa, R.
    Rose, L.
    Sugimoto, D.
    Araki, E.
    Chu, P-L
    Wijayasingh, N.
    Norwood, P.
    Subramanian, G.
    DIABETIC MEDICINE, 2017, 34 : 145 - 146
  • [8] Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
    Lee, Byung-Wan
    Cho, Young Min
    Kim, Sin Gon
    Ko, Seung-Hyun
    Lim, Soo
    Dahaoui, Amine
    Jeong, Jin Sook
    Lim, Hyo Jin
    Yu, Jae Myung
    DIABETES THERAPY, 2024, 15 (02) : 547 - 563
  • [9] Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
    Byung-Wan Lee
    Young Min Cho
    Sin Gon Kim
    Seung-Hyun Ko
    Soo Lim
    Amine Dahaoui
    Jin Sook Jeong
    Hyo Jin Lim
    Jae Myung Yu
    Diabetes Therapy, 2024, 15 : 547 - 563
  • [10] Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in subjects with Type 2 diabetes (SUSTAIN 1)
    Sorli, C.
    Harashima, S-I
    Tsoukas, G.
    Unger, J.
    Karsbol, J. D.
    Bain, S.
    DIABETIC MEDICINE, 2017, 34 : 145 - 145
12345